Bruker Corp. (Nasdaq:BRKR) has debuted new technologies for spatial multiomics, single-cell proteomics and cell-line, tissue and plasma proteomics cancer research.
The company announced the new offerings at the American Association for Cancer Research (AACR) Annual Meeting 2022.
Bruker is also building on its strategic investment in AmberGen, a Boston-based life science technology focused on photonic technology. In particular, the companies are exploring new applications of the Ambergen Miralys peptide-code antibody kits used with the Bruker timsTOF flex novel MALDI HiPLEX-IHC workflow for targeted protein expression profiling in tissue.
According to the companies, using the two technologies in tandem can yield highly multiplexed images of target proteins in a wide field of view.
“Spatial protein expression mapping can elucidate processes in immuno-oncology and in TME and metastasis research,” said Dr. Michael L. Easterling, Bruker Director of Imaging Life Sciences Mass Spectrometry, in a press release. “The MALDI HiPLEX IHC workflow based on AmberGen’s peptide-encoded antibody panels provides targeted protein localization and adds the capability to map important lipids, glycan and metabolite markers on the same tissue section.”
Also, at the AACR Annual Meeting, Bruker is displaying the capabilities of the CellScape instrument for high-precision targeted spatial proteomics.
Filed Under: Drug Discovery and Development